19.04.2010
Neurimmune received ZKB TECHNOPARK® Pioneer Award
The Swiss biotechnology company Neurimmune Therapeutics AG received the ZKB TECHNOPARK® Pioneer Award endowed with nearly CHF 100'000 for its unique and promising avenue of research known as RTM™ (Reverse Translational Medicine) for the treatment and cure of Alzheimer's disease.
Neurimmune Therpeutics was founded in 2006 and received the CTI Start-up Label in September 2007.
Two months later, Neurimmune Therapeutics partnered with Biogen Idec Inc., a leading biopharmaceutical company, to develop and commercialize novel treatments for Alzheimer's disease.
For more information go to www.neurimmune.com